Staphylococcus aureus vaccine development on track safe and immunogenic in Phase I clinical trials
The data show that the vaccine is safe and generally well tolerated. Immune responses were observed within several weeks following vaccination and these immune responses persisted throughout the course of the study.
"We are very pleased that the vaccine candidate, for which the antigen was identified by our proprietary AIP® technology, delivered promising clinical data, and look forward to its further clinical development ", states Gerd Zettlmeissl, CEO of Intercell. "These data underline the high potential of our AIP® technology for the identification of other bacterial vaccine product candidates inhouse or in collaboration with leading vaccine companies".
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.